Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors

被引:71
|
作者
Virag, T
Elrod, DB
Liliom, K
Sardar, VM
Parrill, AL
Yokoyama, K
Durgam, G
Deng, WL
Miller, DD
Tigyi, G
机构
[1] Univ Tennessee, Hlth Sci Ctr, Dept Physiol, Memphis, TN 38163 USA
[2] Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN 38163 USA
[3] Univ Memphis, Dept Chem, Memphis, TN 38152 USA
[4] Univ Memphis, Computat Res Mat Inst, Memphis, TN 38152 USA
[5] Hungarian Acad Sci, Inst Enzymol, Budapest, Hungary
关键词
D O I
10.1124/mol.63.5.1032
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A more complete understanding of the physiological and pathological role of lysophosphatidic acid (LPA) requires receptor subtype-specific agonists and antagonists. Here, we report the synthesis and pharmacological characterization of fatty alcohol phosphates (FAP) containing saturated hydrocarbon chains from 4 to 22 carbons in length. Selection of FAP as the lead structure was based on computational modeling as a minimal structure that satisfies the two-point pharmacophore developed earlier for the interaction of LPA with its receptors. Decyl and dodecyl FAPs (FAP-10 and FAP-12) were specific agonists of LPA(2) (EC50 = 3.7 +/- 0.2 muM and 700 +/- 22 nM, respectively), yet selective antagonists of LPA(3) (K-i = 90 nM for FAP-12) and FAP-12 was a weak antagonist of LPA(1). Neither LPA(1) nor LPA(3) receptors were activated by FAPs; in contrast, LPA(2) was activated by FAPs with carbon chains between 10 and 14. Computational modeling was used to evaluate the interaction between individual FAPs (8 to 18) with LPA(2) by docking each compound in the LPA binding site. FAP-12 displayed the lowest docked energy, consistent with its lower observed EC50. The inhibitory effect of FAP showed a strong hydrocarbon chain length dependence with C12 being optimum in the Xenopus laevis oocytes and in LPA(3)-expressing RH7777 cells. FAP-12 did not activate or interfere with several other G-protein-coupled receptors, including S1P-induced responses through S1P(1,2,3,5) receptors. These data suggest that FAPs are ligands of LPA receptors and that FAP-10 and FAP-12 are the first receptor subtype-specific agonists for LPA(2).
引用
收藏
页码:1032 / 1042
页数:11
相关论文
共 50 条
  • [1] Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors
    Virag, T
    Elrod, DB
    Liliom, K
    Sardar, VM
    Parrill, AL
    Yokoyama, K
    Durgam, G
    Miller, DD
    Tigyi, GJ
    [J]. FASEB JOURNAL, 2003, 17 (04): : A169 - A169
  • [2] Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors
    Fischer, DJ
    Nusser, N
    Virag, T
    Yokoyama, K
    Wang, DA
    Baker, DL
    Bautista, D
    Parrill, AL
    Tigyi, G
    [J]. MOLECULAR PHARMACOLOGY, 2001, 60 (04) : 776 - 784
  • [3] Darmstoff analogues: Subtype-Selective agonists and antagonists of LPA receptors.
    Gududuru, V
    Walkers, MD
    Tsukahara, R
    Fujiwara, Y
    Yasuda, S
    Tigyi, G
    Miller, DD
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U121 - U121
  • [4] Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques
    Rother, E
    Brandl, R
    Baker, DL
    Goyal, P
    Gebhard, H
    Tigyi, G
    Siess, W
    [J]. CIRCULATION, 2003, 108 (06) : 741 - 747
  • [5] Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors
    Gududuru, V
    Zeng, K
    Tsukahara, R
    Makarova, N
    Fujiwara, Y
    Pigg, KR
    Baker, DL
    Tigyi, G
    Miller, DD
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (02) : 451 - 456
  • [6] Characterization of a receptor subtype-selective lysophosphatidic acid mimetic
    Hooks, SB
    Ragan, SP
    Hopper, DW
    Honemann, CW
    Durieux, ME
    MacDonald, TL
    Lynch, KR
    [J]. MOLECULAR PHARMACOLOGY, 1998, 53 (02) : 188 - 194
  • [7] Ki16425, a subtype-selective antagonist for EDG-Family lysophosphatidic acid receptors
    Ohta, H
    Sato, K
    Murata, N
    Damirin, A
    Malchinkhuu, E
    Kon, J
    Kimura, T
    Tobo, M
    Yamazaki, Y
    Watanabe, T
    Yagi, M
    Sato, M
    Suzuki, R
    Murooka, H
    Sakai, T
    Nishitoba, T
    Im, DS
    Nochi, H
    Tamoto, K
    Tomura, H
    Okajima, F
    [J]. MOLECULAR PHARMACOLOGY, 2003, 64 (04) : 994 - 1005
  • [8] Subtype-selective antagonists of lysophosphatidic acid-receptors inhibit platelet shape change induced by mildly-oxidized LDL and the lipid core of atherosclerotic plaques
    Rother, E
    [J]. CIRCULATION, 2002, 106 (19) : 43 - 43
  • [9] Binding pockets of the β1- and β2-adrenergic receptors for subtype-selective agonists
    Isogaya, M
    Sugimoto, Y
    Tanimura, R
    Tanaka, R
    Kikkawa, H
    Nagao, T
    Kurose, H
    [J]. MOLECULAR PHARMACOLOGY, 1999, 56 (05) : 875 - 885
  • [10] CHARACTERIZATION OF BOVINE OVARY ANGIOTENSIN-II RECEPTORS USING SUBTYPE-SELECTIVE ANTAGONISTS
    AIYAR, N
    GRIFFIN, E
    EDWARDS, R
    WEINSTOCK, J
    SAMANEN, J
    NAMBI, P
    [J]. PHARMACOLOGY, 1993, 46 (01) : 1 - 8